-
May.192023NEWS
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-control..
-
Apr.282023NEWS
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
-
Mar.292023NEWS
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
-
Mar.152023NEWS
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
-
Mar.152023NEWS
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
-
Mar.062023NEWS
HanAll Biopharma’s Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis
HanAll Biopharma’s Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclim..